ArticleExperimental and therapeutic medicine2016
Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis.European journal of clinical pharmacology · 2018Pooled it
- The Effects and Potential Mechanisms of Moxibustion for Rheumatoid Arthritis-Related Pain: A Randomized, Controlled Trial.Journal of pain research · 2023Trial
- Multifactorial lifestyle interventions in rheumatoid arthritis: a systematic literature review.EULAR rheumatology open · 2026Article
- Clinical evidence on integrated Chinese-Western medicine for rheumatoid arthritis.Integrative medicine research · 2026Article
- Multi-target therapeutic potential of Flavokawain A in rheumatoid arthritis: A mechanistic and translational perspective.Inflammopharmacology · 2026Review
- The role of prostanoids in the retina and optic nerve in health and disease.Progress in retinal and eye research · 2026Review
- Individual and combined effects of somatic and mental disorders on reoperation risk after hip fracture surgery: a nationwide danish cohort study of 110,625 patients.European geriatric medicine · 2026Article
- Therapeutic potential of Boswellia serrata in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFĸB modulation.Inflammopharmacology · 2025Review
- Flavonoids and flavonoid-based nanoparticles for the treatment of arthritis.Inflammopharmacology · 2025Review
- In situ forming gels as subcutaneous delivery systems of curcumin and piperine.Scientific reports · 2025Article
- Cell-Based Therapeutic Strategies for Autoimmune Diseases.ImmunoTargets and therapy · 2025Review
- Bruton's Tyrosine Kinase Inhibitors: A Versatile Therapeutic Approach for Cancer, Autoimmune Disorders, GVHD and COVID-19.Mini reviews in medicinal chemistry · 2025Review
- Disparities in Peripheral Artery Disease-related Mortality in Chronic Inflammatory Disease in the United States from 1999 to 2020.Current cardiology reviews · 2025Article
- Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications.EXCLI journal · 2022Article
- Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis.Inflammopharmacology · 2021Article
- Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases.Experimental and therapeutic medicine · 2019Review
- Targeted Metabolomic Analysis of Serum Fatty Acids for the Prediction of Autoimmune Diseases.Frontiers in molecular biosciences · 2019Article
- Artery compliance in patients with rheumatoid arthritis: results from a case-control study.Clinical rheumatology · 2018Article
- Antinociceptive and anti-inflammatory activities of the Jatropha isabellei dichloromethane fraction and isolation and quantitative determination of jatrophone by UFLC-DAD.Pharmaceutical biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases are highly prevalent chronic disorders and the leading cause of physical disability worldwide, with a marked socio-economic impact. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology with an autoimmune pathogenesis, characterised by arthropathy with chronic, deforming, destructive evolution and multiple systemic manifestations. The management of RA has undergone significant changes as far as objectives and approaches are concerned, ending in the current strategy known as 'treat to target'. The therapeutic array of RA includes several categories of medicinal products, of varying potential. There are several criteria for the classification of medicinal products used against this disease, one of the most important and modern of which divides such substances according to their effects on the progress of the disease: symptom-modifying antirheumatic drugs (including non-steroidal anti-inflammatory drugs and corticoids), disease-modifying antirheumatic drugs (including various substances, such as gold salts, antimalarials, sulfasalazine, D-penicillamine; non-specific immunosuppressive medication, such as methotrexate, cyclophosphamide, azathioprine and leflunomide) and biological therapy is a recent addition, providing new insight into the treatment of this disease. The selection of the optimal therapy for RA should be based on guidelines and recommendations, but also on clinical particular aspects and patient preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.